{"id":17062,"date":"2019-09-06T13:52:02","date_gmt":"2019-09-06T13:52:02","guid":{"rendered":"https:\/\/celonpharma.com\/?p=17062"},"modified":"2019-09-06T13:52:02","modified_gmt":"2019-09-06T13:52:02","slug":"celon-pharma-will-present-the-results-of-a-phase-i-clinical-trial-on-esketamine-at-the-32nd-congress-of-the-european-college-of-neuropsychopharmacology-in-copenhagen","status":"publish","type":"post","link":"https:\/\/celon.group\/en\/2019\/09\/06\/celon-pharma-will-present-the-results-of-a-phase-i-clinical-trial-on-esketamine-at-the-32nd-congress-of-the-european-college-of-neuropsychopharmacology-in-copenhagen\/","title":{"rendered":"Celon Pharma will present the results of a phase I clinical trial on esketamine at the 32nd Congress of the European College of Neuropsychopharmacology in Copenhagen"},"content":{"rendered":"<p>&nbsp;<\/p>\n<p style=\"text-align: justify;\"><span lang=\"EN-GB\">During the 4 days of the Congress, about 6,000 participants from around the world: psychiatrists, neurobiologists and neurologists will discuss the most important scientific reports on diagnostics and brain treatment, from baseline studies to clinical development. <\/span><\/p>\n<p style=\"text-align: justify;\"><span lang=\"EN-GB\">During the Congress, the Clinical Department representatives will present the results in a poster session which will take place on 8 September 2019.<\/span><\/p>\n<p style=\"text-align: justify;\"><span lang=\"EN-GB\">Poster: <strong>Safety and pharmacokinetic study of inhaled Esketamine after a multiple dose in healthy volunteers<\/strong><\/span><\/p>\n<p style=\"text-align: justify;\"><span lang=\"EN-GB\">Presented by: Sylwia Janowska<\/span><\/p>\n<p style=\"text-align: justify;\"><span lang=\"EN-GB\">Poster number: P.164<\/span><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" class=\"size-large wp-image-16777 aligncenter\" src=\"https:\/\/celonpharma.com\/wp-content\/uploads\/2019\/09\/CELON_LI_201909_02-1024x535.png\" alt=\"\" width=\"1024\" height=\"535\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&nbsp; During the 4 days of the Congress, about 6,000 participants from around the world: psychiatrists, neurobiologists and neurologists will discuss the most important scientific reports on diagnostics and brain treatment, from baseline studies to clinical development. During the Congress, the Clinical Department representatives will present the results in a poster session which will take<a class=\"excerpt-read-more float-right\" href=\"https:\/\/celon.group\/en\/2019\/09\/06\/celon-pharma-will-present-the-results-of-a-phase-i-clinical-trial-on-esketamine-at-the-32nd-congress-of-the-european-college-of-neuropsychopharmacology-in-copenhagen\/\" title=\"ReadCelon Pharma will present the results of a phase I clinical trial on esketamine at the 32nd Congress of the European College of Neuropsychopharmacology in Copenhagen\">Read more &raquo;<\/a><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[26],"tags":[],"class_list":["post-17062","post","type-post","status-publish","format-standard","hentry","category-general-en"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v24.8.1 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Celon Pharma will present the results of a phase I clinical trial on esketamine at the 32nd Congress of the European College of Neuropsychopharmacology in Copenhagen - CelonGROUP<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"http:\/\/celon.group\/en\/2019\/09\/06\/celon-pharma-will-present-the-results-of-a-phase-i-clinical-trial-on-esketamine-at-the-32nd-congress-of-the-european-college-of-neuropsychopharmacology-in-copenhagen\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Celon Pharma will present the results of a phase I clinical trial on esketamine at the 32nd Congress of the European College of Neuropsychopharmacology in Copenhagen - CelonGROUP\" \/>\n<meta property=\"og:description\" content=\"&nbsp; During the 4 days of the Congress, about 6,000 participants from around the world: psychiatrists, neurobiologists and neurologists will discuss the most important scientific reports on diagnostics and brain treatment, from baseline studies to clinical development. During the Congress, the Clinical Department representatives will present the results in a poster session which will takeRead more &raquo;\" \/>\n<meta property=\"og:url\" content=\"http:\/\/celon.group\/en\/2019\/09\/06\/celon-pharma-will-present-the-results-of-a-phase-i-clinical-trial-on-esketamine-at-the-32nd-congress-of-the-european-college-of-neuropsychopharmacology-in-copenhagen\/\" \/>\n<meta property=\"og:site_name\" content=\"CelonGROUP\" \/>\n<meta property=\"article:published_time\" content=\"2019-09-06T13:52:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/celonpharma.com\/wp-content\/uploads\/2019\/09\/CELON_LI_201909_02-1024x535.png\" \/>\n<meta name=\"author\" content=\"Ma\u0142gorzata Siewierska\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Ma\u0142gorzata Siewierska\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"http:\/\/celon.group\/en\/2019\/09\/06\/celon-pharma-will-present-the-results-of-a-phase-i-clinical-trial-on-esketamine-at-the-32nd-congress-of-the-european-college-of-neuropsychopharmacology-in-copenhagen\/\",\"url\":\"http:\/\/celon.group\/en\/2019\/09\/06\/celon-pharma-will-present-the-results-of-a-phase-i-clinical-trial-on-esketamine-at-the-32nd-congress-of-the-european-college-of-neuropsychopharmacology-in-copenhagen\/\",\"name\":\"Celon Pharma will present the results of a phase I clinical trial on esketamine at the 32nd Congress of the European College of Neuropsychopharmacology in Copenhagen - CelonGROUP\",\"isPartOf\":{\"@id\":\"https:\/\/celon.group\/en\/#website\"},\"primaryImageOfPage\":{\"@id\":\"http:\/\/celon.group\/en\/2019\/09\/06\/celon-pharma-will-present-the-results-of-a-phase-i-clinical-trial-on-esketamine-at-the-32nd-congress-of-the-european-college-of-neuropsychopharmacology-in-copenhagen\/#primaryimage\"},\"image\":{\"@id\":\"http:\/\/celon.group\/en\/2019\/09\/06\/celon-pharma-will-present-the-results-of-a-phase-i-clinical-trial-on-esketamine-at-the-32nd-congress-of-the-european-college-of-neuropsychopharmacology-in-copenhagen\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/celonpharma.com\/wp-content\/uploads\/2019\/09\/CELON_LI_201909_02-1024x535.png\",\"datePublished\":\"2019-09-06T13:52:02+00:00\",\"author\":{\"@id\":\"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf\"},\"breadcrumb\":{\"@id\":\"http:\/\/celon.group\/en\/2019\/09\/06\/celon-pharma-will-present-the-results-of-a-phase-i-clinical-trial-on-esketamine-at-the-32nd-congress-of-the-european-college-of-neuropsychopharmacology-in-copenhagen\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"http:\/\/celon.group\/en\/2019\/09\/06\/celon-pharma-will-present-the-results-of-a-phase-i-clinical-trial-on-esketamine-at-the-32nd-congress-of-the-european-college-of-neuropsychopharmacology-in-copenhagen\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"http:\/\/celon.group\/en\/2019\/09\/06\/celon-pharma-will-present-the-results-of-a-phase-i-clinical-trial-on-esketamine-at-the-32nd-congress-of-the-european-college-of-neuropsychopharmacology-in-copenhagen\/#primaryimage\",\"url\":\"https:\/\/celonpharma.com\/wp-content\/uploads\/2019\/09\/CELON_LI_201909_02-1024x535.png\",\"contentUrl\":\"https:\/\/celonpharma.com\/wp-content\/uploads\/2019\/09\/CELON_LI_201909_02-1024x535.png\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"http:\/\/celon.group\/en\/2019\/09\/06\/celon-pharma-will-present-the-results-of-a-phase-i-clinical-trial-on-esketamine-at-the-32nd-congress-of-the-european-college-of-neuropsychopharmacology-in-copenhagen\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/celon.group\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Celon Pharma will present the results of a phase I clinical trial on esketamine at the 32nd Congress of the European College of Neuropsychopharmacology in Copenhagen\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/celon.group\/en\/#website\",\"url\":\"https:\/\/celon.group\/en\/\",\"name\":\"CelonGROUP\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/celon.group\/en\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf\",\"name\":\"Ma\u0142gorzata Siewierska\",\"url\":\"https:\/\/celon.group\/en\/author\/malgorzata-siewierska\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Celon Pharma will present the results of a phase I clinical trial on esketamine at the 32nd Congress of the European College of Neuropsychopharmacology in Copenhagen - CelonGROUP","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"http:\/\/celon.group\/en\/2019\/09\/06\/celon-pharma-will-present-the-results-of-a-phase-i-clinical-trial-on-esketamine-at-the-32nd-congress-of-the-european-college-of-neuropsychopharmacology-in-copenhagen\/","og_locale":"en_US","og_type":"article","og_title":"Celon Pharma will present the results of a phase I clinical trial on esketamine at the 32nd Congress of the European College of Neuropsychopharmacology in Copenhagen - CelonGROUP","og_description":"&nbsp; During the 4 days of the Congress, about 6,000 participants from around the world: psychiatrists, neurobiologists and neurologists will discuss the most important scientific reports on diagnostics and brain treatment, from baseline studies to clinical development. During the Congress, the Clinical Department representatives will present the results in a poster session which will takeRead more &raquo;","og_url":"http:\/\/celon.group\/en\/2019\/09\/06\/celon-pharma-will-present-the-results-of-a-phase-i-clinical-trial-on-esketamine-at-the-32nd-congress-of-the-european-college-of-neuropsychopharmacology-in-copenhagen\/","og_site_name":"CelonGROUP","article_published_time":"2019-09-06T13:52:02+00:00","og_image":[{"url":"https:\/\/celonpharma.com\/wp-content\/uploads\/2019\/09\/CELON_LI_201909_02-1024x535.png","type":"","width":"","height":""}],"author":"Ma\u0142gorzata Siewierska","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Ma\u0142gorzata Siewierska"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"http:\/\/celon.group\/en\/2019\/09\/06\/celon-pharma-will-present-the-results-of-a-phase-i-clinical-trial-on-esketamine-at-the-32nd-congress-of-the-european-college-of-neuropsychopharmacology-in-copenhagen\/","url":"http:\/\/celon.group\/en\/2019\/09\/06\/celon-pharma-will-present-the-results-of-a-phase-i-clinical-trial-on-esketamine-at-the-32nd-congress-of-the-european-college-of-neuropsychopharmacology-in-copenhagen\/","name":"Celon Pharma will present the results of a phase I clinical trial on esketamine at the 32nd Congress of the European College of Neuropsychopharmacology in Copenhagen - CelonGROUP","isPartOf":{"@id":"https:\/\/celon.group\/en\/#website"},"primaryImageOfPage":{"@id":"http:\/\/celon.group\/en\/2019\/09\/06\/celon-pharma-will-present-the-results-of-a-phase-i-clinical-trial-on-esketamine-at-the-32nd-congress-of-the-european-college-of-neuropsychopharmacology-in-copenhagen\/#primaryimage"},"image":{"@id":"http:\/\/celon.group\/en\/2019\/09\/06\/celon-pharma-will-present-the-results-of-a-phase-i-clinical-trial-on-esketamine-at-the-32nd-congress-of-the-european-college-of-neuropsychopharmacology-in-copenhagen\/#primaryimage"},"thumbnailUrl":"https:\/\/celonpharma.com\/wp-content\/uploads\/2019\/09\/CELON_LI_201909_02-1024x535.png","datePublished":"2019-09-06T13:52:02+00:00","author":{"@id":"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf"},"breadcrumb":{"@id":"http:\/\/celon.group\/en\/2019\/09\/06\/celon-pharma-will-present-the-results-of-a-phase-i-clinical-trial-on-esketamine-at-the-32nd-congress-of-the-european-college-of-neuropsychopharmacology-in-copenhagen\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["http:\/\/celon.group\/en\/2019\/09\/06\/celon-pharma-will-present-the-results-of-a-phase-i-clinical-trial-on-esketamine-at-the-32nd-congress-of-the-european-college-of-neuropsychopharmacology-in-copenhagen\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"http:\/\/celon.group\/en\/2019\/09\/06\/celon-pharma-will-present-the-results-of-a-phase-i-clinical-trial-on-esketamine-at-the-32nd-congress-of-the-european-college-of-neuropsychopharmacology-in-copenhagen\/#primaryimage","url":"https:\/\/celonpharma.com\/wp-content\/uploads\/2019\/09\/CELON_LI_201909_02-1024x535.png","contentUrl":"https:\/\/celonpharma.com\/wp-content\/uploads\/2019\/09\/CELON_LI_201909_02-1024x535.png"},{"@type":"BreadcrumbList","@id":"http:\/\/celon.group\/en\/2019\/09\/06\/celon-pharma-will-present-the-results-of-a-phase-i-clinical-trial-on-esketamine-at-the-32nd-congress-of-the-european-college-of-neuropsychopharmacology-in-copenhagen\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/celon.group\/en\/"},{"@type":"ListItem","position":2,"name":"Celon Pharma will present the results of a phase I clinical trial on esketamine at the 32nd Congress of the European College of Neuropsychopharmacology in Copenhagen"}]},{"@type":"WebSite","@id":"https:\/\/celon.group\/en\/#website","url":"https:\/\/celon.group\/en\/","name":"CelonGROUP","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/celon.group\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/celon.group\/en\/#\/schema\/person\/e0ffc863fc928f3fd9bd67757492badf","name":"Ma\u0142gorzata Siewierska","url":"https:\/\/celon.group\/en\/author\/malgorzata-siewierska\/"}]}},"_links":{"self":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/posts\/17062","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/comments?post=17062"}],"version-history":[{"count":0,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/posts\/17062\/revisions"}],"wp:attachment":[{"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/media?parent=17062"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/categories?post=17062"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/celon.group\/en\/wp-json\/wp\/v2\/tags?post=17062"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}